U.S. Chemicals Stock News

Phase 3 REVEAL-1 results put elegrobart in focus Viridian Therapeutics (VRDN) just reported statistically significant, positive topline data from its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease, a material update that reshapes how you might look at the stock. See our latest analysis for Viridian Therapeutics. The REVEAL-1 update lands after a volatile stretch, with the share price at $14.95, a 7 day share price return of 7.55% but a 90 day share price return of 53.27%,...

What recent returns say about Freedom Holding Freedom Holding (FRHC) has drawn attention after a recent share price move, with the stock showing a 0.2% decline over the past day but double digit gains over the past month. See our latest analysis for Freedom Holding. Putting the recent move in context, Freedom Holding’s 30 day share price return of 14.28% and year to date gain of 21.42%, alongside a 5 year total shareholder return of 205.72%, indicate that momentum has been building over both...

The United States market has shown robust performance, rising 3.1% over the last week and climbing 27% in the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks that are perceived as undervalued can be particularly appealing, especially when insider actions suggest confidence in their potential.

The United States market has shown robust performance, rising 3.1% over the last week and 27% over the past year, with earnings projected to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer opportunities for investors seeking to capitalize on discrepancies between current stock prices and their intrinsic values.

Over the last 7 days, the United States market has risen by 3.1%, contributing to a robust 27% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this thriving environment, identifying growth companies with strong insider ownership can be key as it often signals confidence in their long-term potential and alignment of interests between management and shareholders.

The United States market has shown robust performance, climbing 3.1% over the last week and 27% over the past year, with earnings projected to grow by 16% annually. In this context of market growth, identifying stocks with strong financials can be crucial for investors seeking potential opportunities. Penny stocks, though often seen as a term from earlier market days, still represent a segment where smaller or newer companies might offer both affordability and significant growth potential.

The United States market has shown robust performance, rising 3.1% over the last week and climbing 27% in the past year, with anticipated annual earnings growth of 16% in the years ahead. In this thriving environment, identifying stocks that offer unique value propositions and strong potential for growth can be key to uncovering hidden opportunities.

General American Investors Company: recent performance in focus General American Investors Company (GAM) has attracted fresh attention after recent price moves, with returns of 0.6% over the past day and about 4.1% over the past week shaping investor interest. See our latest analysis for General American Investors Company. At a latest share price of $61.71, the stock’s recent 7 day share price return of 4.1% sits alongside a 1 year total shareholder return of 37.8%. This suggests momentum has...

The Morning Bull - US Market Morning Update Monday, Apr, 13 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.6% and Nasdaq 100 futures weaker by roughly 0.7%, as investors react to a fresh inflation shock and higher energy costs. March US consumer prices rose 0.9% month on month, while energy prices are up 12.5% over the past year, signaling that everyday costs from fuel to utilities remain under pressure. Brent crude above US$102 adds to...

Grace Therapeutics, Inc. ( NASDAQ:GRCE ) is possibly approaching a major achievement in its business, so we would like...

Rapid7, Inc. ( NASDAQ:RPD ), might not be a large cap stock, but it saw significant share price movement during recent...

Zentalis Pharmaceuticals (ZNTL) has drawn fresh investor attention after selecting a 400mg once daily, 5-days-on, 2-days-off azenosertib regimen as the optimal monotherapy dose in platinum resistant ovarian cancer. See our latest analysis for Zentalis Pharmaceuticals. The azenosertib update has arrived alongside intense trading interest, with a 1 day share price return of 49.55% and a year to date share price return of 382.48%. The 1 year total shareholder return sits at 437.40%, but the 3...

If you are wondering whether Westlake's current share price lines up with its underlying worth, this article breaks down what the numbers actually say about value. Westlake's shares last closed at US$118.37, with returns of 5.6% over 30 days, 59.6% year to date, and 35.5% over the past year. This indicates that the market has been repricing the stock. Recent market attention on Westlake has focused on how the business fits into the broader US materials sector and how investors are weighing...

If you are wondering whether Humana's current share price fairly reflects its potential, you are not alone. This article walks through what the numbers are actually saying about value. Humana recently closed at US$192.15, with a 7 day return of 8.1%, a 30 day return of 16.2%, but a year to date return of a 27.3% decline and a 1 year return of a 33.8% decline that gives important context for long term holders. Investors have been reacting to ongoing headlines around US healthcare policy,...

Ausbil Investment Management has disclosed H2O America (NasdaqGS:HTO) as its largest portfolio holding. ATLAS Infrastructure Partners has reported owning more than 10% of H2O America. These institutional ownership changes highlight a shift in H2O America's shareholder base that has not been widely discussed. For you as an investor, concentrated positions like Ausbil’s and a stake of more than 10% from ATLAS Infrastructure Partners can change how H2O America is viewed in the market. Large,...

U.S. Representative Gilbert Ray Cisneros, Jr. recently disclosed a personal purchase of Cathay General Bancorp (NasdaqGS:CATY) shares. The transaction adds a new political figure to the shareholder base of Cathay General Bancorp, which has previously drawn attention for executive insider activity. The purchase comes with Cathay General Bancorp shares trading around $53.47. Cathay General Bancorp, trading under NasdaqGS:CATY, has seen its shares at about $53.47, with recent returns of 5.7%...

IMAX (NYSE:IMAX) announced that CEO Richard Gelfond has taken a temporary medical leave of absence. The company has described the move as temporary, with existing leadership expected to oversee operations during his absence. IMAX runs a global network of premium large format cinemas and technology partnerships, placing it at the center of the theatrical side of the film industry. The company is closely tied to major studio release schedules and audience demand for big screen experiences...

Lotus Technology Inc. has reported its fourth-quarter and full-year 2025 results, with revenue falling to US$163.34 million for the quarter and US$519.10 million for the year, while net losses narrowed to US$85.77 million and US$464.22 million respectively compared with the prior year. Against this backdrop of shrinking sales but smaller losses, Lotus has also launched its new “For Me” hyper SUV in Beijing, showcasing its X-Hybrid Architecture and underscoring a push toward high-performance...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

In the past quarter, UniFirst Corporation reported second-quarter 2026 sales of US$622.51 million, up from US$602.22 million a year earlier, while net income declined to US$20.48 million and diluted earnings per share from continuing operations fell to US$1.13. Over the first six months of fiscal 2026, UniFirst grew sales to US$1,243.82 million but saw net income and diluted earnings per share from continuing operations fall to US$54.85 million and US$3.02 respectively, highlighting that...

We wouldn't blame Box, Inc. ( NYSE:BOX ) shareholders if they were a little worried about the fact that Eliahu...

Neogen has agreed to sell its Genomics business to Zoetis as part of a wider portfolio reshaping. The company has completed the divestiture of its Cleaners and Disinfectants business. Neogen is implementing a major restructuring, including a 10% global headcount reduction. These actions concentrate the business around its core Food Safety segment and streamline operations. For investors watching NasdaqGS:NEOG, these moves come after a mixed share price history. The stock is at $9.42, with a...

If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key is to look closely at what the current price actually reflects. The stock has posted returns of 3.9% over the last 7 days, 8.8% over 30 days, 12.2% year to date, and 93.2% over the past year, which naturally raises questions about how much of the story is already priced in and how risk is being perceived. Recent attention on Jazz Pharmaceuticals has centered on its...

Medpace Holdings (NasdaqGS:MEDP) is facing multiple shareholder class action lawsuits tied to alleged false and misleading statements about its book to bill ratio and backlog cancellation rates. Investors claim they suffered losses after company disclosures, with recent insider stock sales by the CEO shortly before negative updates adding to concerns. The litigation focuses on whether management provided overly optimistic projections that did not align with internal business conditions. For...